September 24, 2025 |
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™ across the health and life sciences sector.

We are proud to announce the strategic appointment of two senior executives to our leadership team – advancing innovation, operational excellence, and digital transformation across the organization.Â
Joining the Executive Team are Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer. These appointments strengthen our ability to deliver Intelligent Commercialization™ – seamlessly connecting science, technology, and human expertise to unlock value across every stage of the health and life sciences journey.Â
Mary-Kate, who served as Vice President, Global & Corporate Strategy since 2022, now joins the Executive Team as Chief Strategy & Innovation Officer. In this role, she will lead corporate strategy, innovation, global marketing, and brand development.Â
Since joining Inizio in 2021, following the merger of UDG Healthcare and Huntsworth, Mary-Kate has played a pivotal role in shaping the integrated corporate strategy and aligning strategic priorities across the business. As Chief Strategy & Innovation Officer, she will accelerate our Intelligent Commercialization™ approach – harnessing innovation, strategy realization, and AI-driven transformation, with a focus on:Â
Prior to joining Inizio, Mary-Kate built a tenured career in management consulting, working with executive teams across healthcare, financial services, and government sectors to lead large-scale transformation and growth programs.Â
Gavin McShera, who has served as Inizio’s CIO since 2021, now joins our Executive Team. With three decades of global experience in technology leadership across healthcare, retail, finance, aviation, and the public sector, Gavin continues to oversee our enterprise technology strategy, while playing a broader role in shaping organizational leadership.Â
As CIO, Gavin oversees our enterprise technology strategy, focusing on:Â
Before joining UDG Healthcare in 2021, Gavin served as Group CIO at Applegreen PLC and held roles at Microsoft and as an independent consultant.Â
With these appointments, we reinforce our commitment to being a market-leading, trusted commercialization partner for health and life sciences companies worldwide. At Inizio, we bring together data, technology, and multidisciplinary expertise to simplify complexity, reduce risk, and deliver consistent value across the commercialization journey.Â
Learn more about our leadership team. Â
This content was provided by Inizio
Latest Content from Inizio
Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets
As technology has evolved, so too has the world of qualitative research
Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high...
We are delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Representing Research Partnership is Business Development Manager, Fara Mboge. He will be on hand to...
Research Partnership is proud to support Forever Angels in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania
Published in eyeforpharma April 2016 by Rachel Howard
Within the pharmaceutical industry, there is an increasing need for market research teams to share the insights with their key internal stakeholders, from marketing and brand managers to sales reps...
Research Partnership is delighted to announce promotions and new starters in the UK and further appointments in the US and Singapore offices
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...
In emerging markets where primary care systems do not exist, the patient is the only constant in the journey
